Abbott Laboratories $ABT Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp reduced its position in Abbott Laboratories (NYSE:ABT - Free Report) by 10.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,716,325 shares of the healthcare product maker's stock after selling 190,235 shares during the quarter. Fifth Third Bancorp owned about 0.10% of Abbott Laboratories worth $155,739,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of ABT. Bank Hapoalim BM lifted its stake in shares of Abbott Laboratories by 80.7% in the 2nd quarter. Bank Hapoalim BM now owns 12,765 shares of the healthcare product maker's stock worth $1,158,000 after acquiring an additional 5,699 shares during the period. North Dakota State Investment Board raised its holdings in Abbott Laboratories by 2.6% during the second quarter. North Dakota State Investment Board now owns 51,490 shares of the healthcare product maker's stock worth $4,672,000 after purchasing an additional 1,315 shares in the last quarter. VCI Wealth Management LLC raised its holdings in Abbott Laboratories by 45.3% during the second quarter. VCI Wealth Management LLC now owns 27,788 shares of the healthcare product maker's stock worth $2,522,000 after purchasing an additional 8,660 shares in the last quarter. Golden Reserve Retirement LLC lifted its position in Abbott Laboratories by 155.2% in the second quarter. Golden Reserve Retirement LLC now owns 9,138 shares of the healthcare product maker's stock valued at $829,000 after purchasing an additional 5,557 shares during the period. Finally, 71 West Capital Partners boosted its holdings in Abbott Laboratories by 35.8% in the 2nd quarter. 71 West Capital Partners now owns 12,065 shares of the healthcare product maker's stock valued at $1,095,000 after purchasing an additional 3,182 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first continuous monitor designed to track both glucose and ketone levels. The device could strengthen Abbott’s FreeStyle Libre ecosystem, help identify rising ketones before diabetic ketoacidosis emergencies, and support compatibility with automated insulin-delivery systems. Reuters article
• Positive Sentiment: TD Cowen raised its price target for ABT to $135 from $115 and maintained a “buy” rating. The upgrade signals confidence in Abbott’s growth prospects, particularly in continuous glucose monitoring and medical devices. Benzinga article
• Positive Sentiment: Medtronic’s MiniMed Flex insulin pump has begun shipping with an Abbott-made glucose sensor, expanding the potential distribution and application of Abbott’s sensor technology in automated insulin delivery. MedTech Dive article
• Neutral Sentiment: Recent comparisons portray Abbott as a relatively attractive healthcare and continuous glucose monitoring investment, citing valuation, liquidity and price-target upside. These assessments may support sentiment but do not represent new company operating results. Yahoo Finance article
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formulas contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Insider Monkey article
• Negative Sentiment: Diagnostics growth remains uneven: strong routine testing and 13% cancer-diagnostics growth are being partly offset by weaker respiratory testing demand. This could temper near-term revenue momentum. Yahoo Finance article

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. TD Cowen increased their target price on Abbott Laboratories from $115.00 to $135.00 and gave the stock a "buy" rating in a research note on Tuesday. UBS Group lowered their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Citigroup increased their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Royal Bank Of Canada reissued an "outperform" rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Stock Down 0.5%

Shares of NYSE ABT opened at $116.12 on Wednesday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a market capitalization of $200.94 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm's 50-day moving average is $101.15 and its two-hundred day moving average is $100.09.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. During the same period last year, the company posted $1.26 EPS. The company's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source